NRX Pharmaceuticals (NRXP.US) Financial Statements - Balance Sheet/Income Statement/Cash Flow - Longbridge

Quote List Quote List

Event Tracking

Nov14

NRX Pharmaceuticals released FY2025 9 Months earnings on November 14 Pre-Market (EST), actual revenue USD 242K, actual EPS USD -1.5811

14:30

NRX Pharmaceuticals released FY2025 Q3 earnings on November 14 Pre-Market (EST), actual revenue USD 242K (forecast USD 6.075M), actual EPS USD -0.2649 (forecast USD -0.0325)

14:30

Nov10

NRX Pharmaceuticals to Release FY2025 Q3 Earnings on November 17, Pre-Market EST; Forecast Revenue USD 6.075 M, EPS USD -0.0325

00:05

Oct6

Background introduction of NRx Pharmaceuticals and HOPE Therapeutics

13:02

Sep29

KETAFREE™ Provides Non-Preservative Intravenous Ketamine Formula

13:03

Sep26

NRX Pharmaceuticals Receives FDA Approval for New Drug Formulation

12:02

Schedules & Filings

Schedules

Filings

Nov14

Earning Release(EST)

FY2025 Q3 Earning Release (USD) Revenue 242 K, Net Income -5.89 M, EPS -0.2649

Aug18

Earning Release(EST)

FY2025 Q2 Earning Release (USD) Net Income -17.58 M, EPS -0.9803

May15

Earning Release(EST)

FY2025 Q1 Earning Release (USD) Net Income -5.512 M, EPS -0.3358

View More

Stock List

Top Gainers

Top Decliners

China Concepts

Symbol

Price

%Chg

Change

View More